MTX-COVAB, a human-derived antibody with potent neutralizing activity against SARS-CoV-2 infection in vitro and in a hamster model of COVID-19

  1. Simone Schmitt
  2. Marcel Weber
  3. Matthias Hillenbrand
  4. Jemima Seidenberg
  5. Andreas Zingg
  6. Catherine Townsend
  7. Barbara Eicher
  8. Justina Rutkauskaite
  9. Peggy Riese
  10. Carlos A. Guzman
  11. Karsten Fischer
  12. Christoph Esslinger
1 evaluations Published on
Read the full article Related papers
This article on Sciety

Abstract

Fast track microfluidic screening of the antibody repertoires of 12 convalescent COVID-19 donors comprising 2.8mio antibodies yielded MTX-COVAB, a human-derived monoclonal antibody with low picomolar neutralization IC50 of SARS-CoV-2. COVAB neutralization potency is on par with the Regeneron cocktail as demonstrated in a comparative neutralization assay. MTX-COVAB shows strong efficacy in vivo and binds to all currently identified clinically relevant variants of SARS-CoV-2. MTX-COVAB completes GMP manufacturing by the end of this year and will be tested in the clinic in March 2021.

Related articles

Related articles are currently not available for this article.